Neurological manifestations and etiological risk factors in patients hospitalized with COVID-19 in Turkey.

IF 0.4 4区医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL Asian Biomedicine Pub Date : 2022-02-01 DOI:10.2478/abm-2022-0004

Nuray Can Usta, Seyfi Kartal, Betul Onal Gunay, Cavit Boz

{"title":"Neurological manifestations and etiological risk factors in patients hospitalized with COVID-19 in Turkey.","authors":"Nuray Can Usta, Seyfi Kartal, Betul Onal Gunay, Cavit Boz","doi":"10.2478/abm-2022-0004","DOIUrl":null,"url":null,"abstract":"Background: Coronavirus disease 2019 (COVID-19) can affect the neurological as well as the respiratory system. Neurological manifestations may involve the central or peripheral nervous systems, or musculoskeletal system. Findings can range from mild presentations, such as headache and anosmia, to severe complications, such as stroke and seizure.Objectives: To evaluate the neurological findings and to determine etiological risk factors for mortality in patients hospitalized for COVID-19.Methods: Medical records of patients with COVID-19 who were hospitalized and sought neurological consultation between March 2020 and March 2021 at a reference pandemic hospital in Turkey were reviewed retrospectively in a cross-sectional study design.Result: We included data from 150 (94 male) patients. Their mean age ± standard deviation was 68.56 ± 16.02 (range 21-97) years. The patients were categorized into 2 groups according to any acute neurological event or progression of neurological disease. Ischemic cerebrovascular events, seizures, and encephalopathy were the most common acute neurological events, while deterioration in consciousness, epileptic seizures, and Parkinson disease were observed in those with progression of neurological disease. Abnormal neurological findings were found at a mean of 7.8 ± 9.7 days following COVID-19 diagnosis and 50 (a third of) patients died. A logistic regression model found that advanced age, increased Modified Charlson Comorbidity Index (MCCI) score, and prolonged duration of hospitalization were factors significantly associated with increased mortality; however, sex and day of abnormal neurological findings after COVID-19 diagnosis were not. Common conditions accompanying neurological events were hypertension, coronary artery disease-heart failure, and diabetes mellitus.Conclusion: COVID-19 may present with neurological symptoms in our Turkish patients and comorbidities are often present.","PeriodicalId":8501,"journal":{"name":"Asian Biomedicine","volume":"16 1","pages":"23-30"},"PeriodicalIF":0.4000,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321161/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Biomedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/abm-2022-0004","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Coronavirus disease 2019 (COVID-19) can affect the neurological as well as the respiratory system. Neurological manifestations may involve the central or peripheral nervous systems, or musculoskeletal system. Findings can range from mild presentations, such as headache and anosmia, to severe complications, such as stroke and seizure.

Objectives: To evaluate the neurological findings and to determine etiological risk factors for mortality in patients hospitalized for COVID-19.

Methods: Medical records of patients with COVID-19 who were hospitalized and sought neurological consultation between March 2020 and March 2021 at a reference pandemic hospital in Turkey were reviewed retrospectively in a cross-sectional study design.

Result: We included data from 150 (94 male) patients. Their mean age ± standard deviation was 68.56 ± 16.02 (range 21-97) years. The patients were categorized into 2 groups according to any acute neurological event or progression of neurological disease. Ischemic cerebrovascular events, seizures, and encephalopathy were the most common acute neurological events, while deterioration in consciousness, epileptic seizures, and Parkinson disease were observed in those with progression of neurological disease. Abnormal neurological findings were found at a mean of 7.8 ± 9.7 days following COVID-19 diagnosis and 50 (a third of) patients died. A logistic regression model found that advanced age, increased Modified Charlson Comorbidity Index (MCCI) score, and prolonged duration of hospitalization were factors significantly associated with increased mortality; however, sex and day of abnormal neurological findings after COVID-19 diagnosis were not. Common conditions accompanying neurological events were hypertension, coronary artery disease-heart failure, and diabetes mellitus.

Conclusion: COVID-19 may present with neurological symptoms in our Turkish patients and comorbidities are often present.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

土耳其COVID-19住院患者的神经学表现和病因危险因素

背景:2019冠状病毒病(COVID-19)可影响神经系统和呼吸系统。神经系统表现可累及中枢或周围神经系统，或肌肉骨骼系统。症状可以从轻微的表现，如头痛和嗅觉丧失，到严重的并发症，如中风和癫痫发作。目的:评估COVID-19住院患者的神经学表现并确定死亡的病因危险因素。方法:采用横断面研究设计，回顾性分析2020年3月至2021年3月在土耳其一家参考大流行医院住院并寻求神经学会诊的COVID-19患者的医疗记录。结果:我们纳入了150例(94例男性)患者的资料。平均年龄±标准差为68.56±16.02岁(21 ~ 97岁)。根据急性神经事件或神经系统疾病进展情况将患者分为两组。缺血性脑血管事件、癫痫发作和脑病是最常见的急性神经系统事件，而在神经系统疾病进展的患者中观察到意识恶化、癫痫发作和帕金森病。新冠肺炎确诊后平均7.8±9.7天出现神经系统异常，50例(三分之一)患者死亡。logistic回归模型发现，高龄、改良Charlson合并症指数(MCCI)评分升高、住院时间延长是死亡率升高的显著因素;然而，在COVID-19诊断后，性别和神经异常表现的日期没有变化。伴随神经系统事件的常见疾病有高血压、冠状动脉疾病-心力衰竭和糖尿病。结论:在我们的土耳其患者中，COVID-19可能出现神经系统症状，并经常出现合并症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Asian Biomedicine 医学-医学：研究与实验

CiteScore

1.20

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Asian Biomedicine: Research, Reviews and News (ISSN 1905-7415 print; 1875-855X online) is published in one volume (of 6 bimonthly issues) a year since 2007. [...]Asian Biomedicine is an international, general medical and biomedical journal that aims to publish original peer-reviewed contributions dealing with various topics in the biomedical and health sciences from basic experimental to clinical aspects. The work and authorship must be strongly affiliated with a country in Asia, or with specific importance and relevance to the Asian region. The Journal will publish reviews, original experimental studies, observational studies, technical and clinical (case) reports, practice guidelines, historical perspectives of Asian biomedicine, clinicopathological conferences, and commentaries Asian biomedicine is intended for a broad and international audience, primarily those in the health professions including researchers, physician practitioners, basic medical scientists, dentists, educators, administrators, those in the assistive professions, such as nurses, and the many types of allied health professionals in research and health care delivery systems including those in training.